Toth Financial Advisory Corp Makes New $1.17 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL

Key Points

• Toth Financial Advisory bought a new stake of 2,000 shares in Madrigal Pharmaceuticals — a position worth about $1.17 million in the fourth quarter.
• Madrigal reported Q results showing a large EPS miss of -$2.57 (vs. $0.04 expected) while revenue beat at $321.08 million, up 210.8% year-over-year, leaving the company still unprofitable.
• Insiders have been net sellers — including the CFO’s sale of 1,982 shares — with 55,612 shares (~$28.33M) sold in the last 90 days; hedge funds/institutions own about 98.5% of the stock and analysts' consensus is a "Moderate Buy" with an average target of $685.31.

Toth Financial Advisory Corp bought a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 2,000 shares of the biopharmaceutical company's stock, valued at approximately $1,165,000.

A number of other hedge funds also recently modified their holdings of MDGL. Mather Group LLC. purchased a new position in shares of Madrigal Pharmaceuticals during the third quarter valued at $33,000. Global Retirement Partners LLC lifted its stake in Madrigal Pharmaceuticals by 221.7% in the 3rd quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 51 shares in the last quarter. First Horizon Corp purchased a new stake in Madrigal Pharmaceuticals in the 3rd quarter worth about $34,000. Aventura Private Wealth LLC acquired a new stake in Madrigal Pharmaceuticals during the 4th quarter worth about $36,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in Madrigal Pharmaceuticals during the 3rd quarter worth about $39,000. Hedge funds and other institutional investors own 98.50% of the company's stock.

Madrigal Pharmaceuticals Stock Performance

Shares of NASDAQ MDGL opened at $546.89 on Friday. The business's 50-day moving average price is $467.44 and its two-hundred day moving average price is $493.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.01 and a quick ratio of 3.77. Madrigal Pharmaceuticals, Inc. has a one year low of $265.00 and a one year high of $615.00. The company has a market capitalization of $12.55 billion, a P/E ratio of -42.49 and a beta of -1.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($2.61). The firm had revenue of $321.08 million for the quarter, compared to analysts' expectations of $310.36 million. Madrigal Pharmaceuticals had a negative return on equity of 43.76% and a negative net margin of 30.08%.The firm's revenue for the quarter was up 210.8% on a year-over-year basis. During the same period last year, the business earned ($2.71) earnings per share. Analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on MDGL shares. Wolfe Research set a $579.00 target price on Madrigal Pharmaceuticals in a report on Tuesday, January 6th. Weiss Ratings restated a "sell (d-)" rating on shares of Madrigal Pharmaceuticals in a report on Thursday, January 22nd. Piper Sandler boosted their price objective on shares of Madrigal Pharmaceuticals from $540.00 to $900.00 and gave the company an "overweight" rating in a research report on Friday, December 19th. TD Cowen reiterated a "buy" rating on shares of Madrigal Pharmaceuticals in a research note on Monday, January 12th. Finally, UBS Group set a $900.00 target price on shares of Madrigal Pharmaceuticals in a research report on Friday, December 19th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Madrigal Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $685.31.

Insider Transactions at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, CFO Mardi Dier sold 1,982 shares of the business's stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $430.87, for a total value of $853,984.34. Following the completion of the sale, the chief financial officer directly owned 12,490 shares of the company's stock, valued at $5,381,566.30. The trade was a 13.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Carole Huntsman sold 910 shares of the stock in a transaction on Monday, January 26th. The stock was sold at an average price of $493.78, for a total transaction of $449,339.80. Following the transaction, the insider owned 9,122 shares in the company, valued at approximately $4,504,261.16. This trade represents a 9.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 55,612 shares of company stock valued at $28,326,065 in the last ninety days. 21.50% of the stock is currently owned by insiders.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company's pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.